European Medicines Agency approves Moderna vaccine

On January 6, the European Medicines Agency (EAL) recommended allowing the use of the Covid-19 vaccine produced by Moderna for people over the age of 18. This is the second vaccine approved in Europe, according to the agency.

The vaccine was found to meet EU standards. ” This vaccine provides us with another tool to overcome the current emergency, ” said Emer Cook, Executive director of the EAL. “The fact that we have a second positive recommendation for a vaccine just one year after the World Health Organization declared a pandemic is a testament to the effort and dedication of all involved.”

Trials have shown that the Moderna vaccine is effective in preventing Covid-19 disease in people over the age of 18. The trials involved 30,000 people, half of whom received the vaccine and the other half received a placebo. The vaccine showed 94.1% effectiveness – only 11 people out of 14,134 test participants who received the vaccine fell ill with Covid-19. In the second group that received a placebo, 185 people became ill with Covid-19.

The vaccine was 90.9% effective for people with chronic diseases and showed high effectiveness in all racial, ethnic and gender groups.

Moderna vaccination involves two injections with a difference of 28 days. The reaction to the vaccine was mild or moderate, the unpleasant effects passed by themselves after a couple of days. Most often, test participants experienced pain at the injection site, fatigue, increased body temperature, could inflame the lymph nodes under the armpits, headache, muscles or joints. Some of the volunteers experienced nausea and vomiting.

Moderna has developed a vaccine based on mRNA technology-it trains the immune system to recognize the coronavirus protein it needs to enter the body’s cells. In case of infection, the immune system recognizes the protein and immediately activates the defense. mRNA does not remain in the body, but breaks down quickly after vaccination.

Cook pointed out that the EAL will continue to monitor data on the safety and effectiveness of vaccines, and the agency’s work will always be based on scientific evidence and dedication to the promise to protect the health of EU residents.

Companies are required to collect information from doctors and medical institutions about the side effects of the vaccine and transmit it to the EAL.

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *